ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Zymeworks Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$25.54+0.51 (+2.04%)
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
98.1%
70M of 71M shares
Institutional holders
203
25 new, 29 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 10 sales
Net sold $4.67M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Rosen | 7,000,000 | 9.49% | 13G (passive) amendment | Mar 31, 2026 |
| Redmile Group, LLC | 4,150,627 | 5.60% | 13G (passive) amendment | Jun 30, 2025 |
| Joseph Edelman | 3,974,579 | 5.40% | 13G (passive) | Apr 8, 2026 |
| Lampert Mark N | 3,938,641 | 5.20% | 13G (passive) amendment | Sep 30, 2025 |
| EcoR1 Capital, LLC | 22,970,388 | 30.70% | 13D (active) amendment | Nov 16, 2025 |
| Oleg Nodelman | 17,699,774 | 25.40% | 13D (active) amendment | Apr 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZYME | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | 32.37% | $600.45M | – | 29.19% |
| Rubric Capital Management LP | 7,000,000 | 9.86% | $182.98M | – | 1.68% |
| BlackRock, Inc. | 4,251,030 | 5.99% | $111.12M | −302,858 | 0.00% |
| Perceptive Advisors LLC | 4,182,953 | 5.89% | $109.34M | +672,875 | 1.64% |
| Bvf Inc/Il | 3,649,142 | 5.14% | $95.39M | −85,000 | 2.44% |
| Assenagon Asset Management S.A. | 2,504,054 | 3.53% | $65.46M | +1,776,068 | 0.04% |
| Morgan Stanley | 2,231,260 | 3.14% | $58.33M | −249,308 | 0.00% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | 2.51% | $46.56M | −126,923 | 0.05% |
| Vanguard Capital Management LLC | 1,558,998 | 2.20% | $40.75M | −146,582 | 0.00% |
| Nextech Invest, Ltd. | 1,113,946 | 1.57% | $29.12M | – | 1.38% |
| State Street Corp | 1,088,216 | 1.53% | $28.45M | +76,439 | 0.00% |
| Dimensional Fund Advisors LP | 994,955 | 1.40% | $26.00M | −144,180 | 0.00% |
| Citadel Advisors LLC | 914,136 | 1.29% | $23.90M | −235,882 | 0.00% |
| Nomura Asset Management International Inc. | 889,802 | 1.25% | $23.26M | New | 0.03% |
| FMR LLC | 702,568 | 0.99% | $18.37M | +35,415 | 0.00% |
| Geode Capital Management, LLC | 692,410 | 0.98% | $18.10M | +32,470 | 0.00% |
| Prosight Management, LP | 674,434 | 0.95% | $17.63M | +135,385 | 3.04% |
| Qube Research & Technologies Ltd | 593,590 | 0.84% | $15.52M | +81,653 | 0.01% |
| Vanguard Portfolio Management LLC | 510,032 | 0.72% | $13.33M | +10,157 | 0.00% |
| Redmile Group, LLC | 491,654 | 0.69% | $12.85M | – | 0.86% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 203 | 70M | 98.1% | 25 / 61 | 73 / 29 | 5M | 6M |
| Q1 2026 | 212 | 70M | 99.1% | 40 / 77 | 58 / 35 | 9M | 7M |
| Q4 2025 | 209 | 71M | 100.0% | 47 / 70 | 63 / 19 | 12M | 14M |
| Q3 2025 | 183 | 74M | 100.0% | 25 / 61 | 65 / 23 | 6M | 8M |
| Q2 2025 | 181 | 76M | 100.0% | 29 / 62 | 55 / 30 | 12M | 7M |
| Q1 2025 | 184 | 71M | 99.5% | 32 / 60 | 64 / 17 | 11M | 5M |
| Q4 2024 | 172 | 66M | 93.7% | 31 / 47 | 61 / 20 | 5M | 6M |
| Q3 2024 | 163 | 67M | 93.9% | 26 / 43 | 52 / 25 | 9M | 7M |
| Q2 2024 | 164 | 68M | 96.2% | 24 / 58 | 55 / 28 | 9M | 17M |
| Q1 2024 | 171 | 78M | 100.0% | 32 / 66 | 39 / 17 | 11M | 2M |
| Q4 2023 | 157 | 70M | 98.4% | 33 / 55 | 40 / 14 | 10M | 3M |
| Q3 2023 | 139 | 62M | 87.9% | 22 / 50 | 39 / 19 | 4M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ZYME | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,508,613 | 2.13% | $39.44M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,207,865 | 1.70% | $31.57M | 0.04% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 600,846 | 0.85% | $15.71M | 1.34% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 512,747 | 0.72% | $11.25M | 0.03% | Jul 31, 2026 |
| iShares Biotechnology ETF | 500,560 | 0.71% | $13.08M | 0.14% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 434,367 | 0.61% | $11.35M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 369,100 | 0.52% | $8.10M | 0.09% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 256,110 | 0.36% | $6.44M | 0.04% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 218,946 | 0.31% | $5.50M | 0.10% | May 29, 2026 |
| U.S. Small Cap Portfolio | 194,463 | 0.27% | $4.27M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 189,632 | 0.27% | $4.16M | 0.03% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 184,050 | 0.26% | $4.04M | 0.09% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 166,863 | 0.24% | $3.66M | 0.05% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 156,803 | 0.22% | $3.44M | 0.15% | Jul 31, 2026 |
| Nomura VIP Small Cap Growth Series | 117,152 | 0.17% | $3.06M | 1.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO, Director | 226,842 | 0.32% | Jan 12, 2026 |
| Mark Hollywood | EVP & Chief Operating Officer | 133,852 | 0.19% | Jul 6, 2026 |
| Paul R. Schneider | EVP, General Counsel | 0 | – | May 15, 2026 |
| Scott Platshon | EVP, Chief Business Officer | 0 | – | Apr 10, 2026 |
| Adam Schayowitz | See Remarks | 0 | – | Apr 10, 2026 |
| Kristin Stafford | EVP, Chief Financial Officer | 0 | – | Apr 7, 2026 |
| Sabeen Mekan | SVP & Chief Medical Officer | 0 | – | Feb 2, 2026 |
| Jeffrey T. L. Smith | EVP & Chief Medical Officer | 26,708 | 0.04% | Jan 12, 2026 |
| Paul Andrew Moore | Chief Scientific Officer | 48,497 | 0.07% | Jan 12, 2026 |
| Leone D. Patterson | EVP, Chief Bus & Fin Officer | 459 | 0.00% | Jan 7, 2026 |
| Brian N. Cherry | Director | 0 | – | Jan 13, 2026 |
| Carlos Campoy | Director | 0 | – | Jan 12, 2026 |
| Gregory Austin Ciongoli | Director | 493,500 | 0.70% | Jan 12, 2026 |
| Alessandra Cesano | Director | 0 | – | Jan 12, 2026 |
| Robert E. Landry | Director | 0 | – | Jan 12, 2026 |
| Susan Mahony | Director | – | – | Jan 12, 2026 |
| Kelvin Neu | Director | – | – | Jan 12, 2026 |
| Oleg Nodelman | Director, 10% owner | 22,970,388 | 32.37% | Jun 27, 2025 |
| EcoR1 Capital, LLC | Director, 10% owner | 17,883,908 | 25.20% | Jun 27, 2025 |
| Derek John Michael Miller | Director | 0 | – | Dec 12, 2024 |
| Nancy Davidson | Director | 0 | – | Dec 12, 2024 |
| Neil Gallagher | Director | 0 | – | Dec 12, 2024 |
| Troy Cox | Director | – | – | Dec 12, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Hollywood EVP & Chief Operating Officer | Jul 6, 2026 | Award | +939 | $22.22 | $20.86K | 133,852 |
| Mark Hollywood EVP & Chief Operating Officer | Jan 12, 2026 | Sale | −6,120 | $22.67 | $138.74K | 132,913 |
| Mark Hollywood EVP & Chief Operating Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 139,033 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 12, 2026 | Sale | −9,310 | $22.67 | $211.06K | 26,708 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 36,018 |
| Kenneth Galbraith Chair & CEO, Director | Jan 12, 2026 | Sale | −30,424 | $22.67 | $689.71K | 226,842 |
| Kenneth Galbraith Chair & CEO, Director | Jan 12, 2026 | Option exercise | +64,000 | – | – | 257,266 |
| Paul Andrew Moore Chief Scientific Officer | Jan 12, 2026 | Sale | −9,560 | $22.67 | $216.73K | 48,497 |
| Paul Andrew Moore Chief Scientific Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 58,057 |
| Leone D. Patterson EVP, Chief Bus & Fin Officer | Jan 6, 2026 | Award | +459 | $10.55 | $4.84K | 459 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 5, 2026 | Sale | −10,538 | $25.10 | $264.50K | 18,352 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 5, 2026 | Option exercise | +20,000 | – | – | 28,890 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Option exercise | +20,000 | – | – | 51,212 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Option exercise | +17,168 | – | – | 40,501 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Sale | −9,289 | $25.10 | $233.15K | 31,212 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Sale | −10,821 | $25.10 | $271.61K | 40,391 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Option exercise | +66,666 | – | – | 224,952 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Sale | −22,657 | $25.10 | $568.69K | 158,286 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Sale | −31,686 | $25.10 | $795.32K | 193,266 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Option exercise | +47,668 | – | – | 180,943 |
| Kenneth Galbraith Chair & CEO, Director | Dec 22, 2025 | Option exercise | +100,000 | – | – | 180,803 |
| Kenneth Galbraith Chair & CEO, Director | Dec 22, 2025 | Sale | −47,528 | $27.02 | $1.28M | 133,275 |
| Gregory Austin Ciongoli Director | Aug 12, 2025 | Award | +415,000 | $12.02 | $4.99M | 488,500 |
| Oleg Nodelman Director, 10% owner | Jun 26, 2025 | Tax withholding | −41 | $12.71 | $521 | 22,970,388 |
| Oleg Nodelman Director, 10% owner | Jun 26, 2025 | Option exercise | +5,086,480 | – | – | 22,970,388 |
| EcoR1 Capital, LLC Director, 10% owner | May 19, 2025 | Buy | +5,919 | $11.78 | $69.73K | 17,883,908 |
| EcoR1 Capital, LLC Director, 10% owner | May 15, 2025 | Buy | +49,502 | $11.43 | $565.81K | 17,877,989 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 17, 2025 | Buy | +54,760 | $11.52 | $630.84K | 17,828,487 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 16, 2025 | Buy | +73,953 | $11.16 | $825.32K | 17,773,727 |
| Oleg Nodelman Director, 10% owner | Apr 4, 2025 | Buy | +196,438 | $11.17 | $2.19M | 17,699,774 |
| Oleg Nodelman Director, 10% owner | Apr 3, 2025 | Buy | +120,770 | $11.84 | $1.43M | 17,503,336 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 2, 2025 | Buy | +74,360 | $11.85 | $881.17K | 17,382,566 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 1, 2025 | Buy | +48,658 | $11.60 | $564.43K | 17,308,206 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 31, 2025 | Buy | +4,397 | $11.75 | $51.66K | 17,259,548 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 26, 2025 | Buy | +43,848 | $12.24 | $536.70K | 17,255,151 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 25, 2025 | Buy | +53,501 | $12.91 | $690.70K | 17,211,303 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 24, 2025 | Buy | +22,689 | $13.08 | $296.77K | 17,157,802 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 21, 2025 | Buy | +31,033 | $12.78 | $396.60K | 17,135,113 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 20, 2025 | Buy | +73,476 | $12.93 | $950.04K | 17,104,080 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 19, 2025 | Buy | +58,306 | $12.64 | $736.99K | 17,030,604 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 18, 2025 | Buy | +113,880 | $12.65 | $1.44M | 16,972,298 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 17, 2025 | Buy | +56,277 | $12.23 | $688.27K | 16,858,418 |
| Oleg Nodelman Director, 10% owner | Mar 13, 2025 | Buy | +468,356 | $12.48 | $5.85M | 16,802,141 |
| Oleg Nodelman Director, 10% owner | Mar 12, 2025 | Buy | +292,934 | $12.25 | $3.59M | 16,333,785 |
| Oleg Nodelman Director, 10% owner | Mar 11, 2025 | Buy | +320,690 | $11.49 | $3.68M | 16,040,851 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 17, 2025 | Buy | +19,748 | $13.87 | $273.90K | 15,720,161 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 16, 2025 | Buy | +121,681 | $13.89 | $1.69M | 15,700,413 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 15, 2025 | Buy | +39,029 | $14.01 | $546.80K | 15,578,732 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 14, 2025 | Buy | +54,500 | $13.56 | $739.02K | 15,539,703 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 13, 2025 | Buy | +74,125 | $13.39 | $992.53K | 15,485,203 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 10, 2025 | Buy | +204,098 | $13.13 | $2.68M | 15,411,078 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 8, 2025 | Buy | +21,021 | $14.07 | $295.77K | 15,206,980 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Option exercise | +47,666 | – | – | 71,428 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Sale | −33,406 | $14.92 | $498.42K | 80,803 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Option exercise | +66,666 | – | – | 114,209 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Sale | −23,885 | $14.92 | $356.36K | 47,543 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Option exercise | +17,166 | – | – | 24,533 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Sale | −9,792 | $14.92 | $146.10K | 14,741 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Sale | −11,408 | $14.92 | $170.21K | 23,333 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Option exercise | +20,000 | – | – | 34,741 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Schayowitz Adam officer | Oct 9, 2026 | 13,832 | $349.40K | Oct 9, 2026 | Vesting of Restricted Stock Units |
| T. L. Smith Jeffrey Former Officer | Mar 6, 2026 | 247,333 | $6.13M | Mar 6, 2026 | Exercise of Options |
| D. Patterson Leone Former officer | Feb 17, 2026 | 31,641 | $715.09K | Feb 17, 2026 | Exercise of options |
| D. Patterson Leone Former officer | Feb 13, 2026 | 128,548 | $2.98M | Feb 13, 2026 | Exercise of options |
| Andrew Moore Paul Officer | Jan 12, 2026 | 9,560 | $221.51K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Hollywood Mark Officer | Jan 12, 2026 | 6,120 | $141.80K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Galbraith Kenneth Officer, Director | Jan 12, 2026 | 30,424 | $704.92K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| D. Patterson Leone Former officer | Jan 12, 2026 | 6,832 | $158.30K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| T. L. Smith Jeffrey Officer | Jan 12, 2026 | 9,310 | $215.71K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Jeffrey T. L. Smith Officer | Jan 5, 2026 | 10,538 | $280.52K | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Andrew Moore Paul Officer | Jan 5, 2026 | 20,110 | $535.33K | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Galbraith Kenneth Officer, Director | Jan 5, 2026 | 54,343 | $1.45M | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Galbraith, Kenneth Officer, Director | Dec 22, 2025 | 47,528 | $1.29M | Dec 22, 2025 | Vesting of Restricted Stock Units |
| John Michael Miller Derek Former Director | Nov 24, 2025 | 118,000 | $2.81M | Nov 24, 2025 | Exercise of options |
| Gallagher Neil Former Director | Nov 21, 2025 | 105,000 | $2.50M | Nov 21, 2025 | Exercise of options |